TY - JOUR
T1 - Biallelic MFSD2A variants associated with congenital microcephaly, developmental delay, and recognizable neuroimaging features
AU - Scala, Marcello
AU - Chua, Geok Lin
AU - Chin, Cheen Fei
AU - Alsaif, Hessa S.
AU - Borovikov, Artem
AU - Riazuddin, Saima
AU - Riazuddin, Sheikh
AU - Chiara Manzini, M.
AU - Severino, Mariasavina
AU - Kuk, Alvin
AU - Fan, Hao
AU - Jamshidi, Yalda
AU - Toosi, Mehran Beiraghi
AU - Doosti, Mohammad
AU - Karimiani, Ehsan Ghayoor
AU - Salpietro, Vincenzo
AU - Dadali, Elena
AU - Baydakova, Galina
AU - Konovalov, Fedor
AU - Lozier, Ekaterina
AU - O’Connor, Emer
AU - Sabr, Yasser
AU - Alfaifi, Abdullah
AU - Ashrafzadeh, Farah
AU - Striano, Pasquale
AU - Zara, Federico
AU - Alkuraya, Fowzan S.
AU - Houlden, Henry
AU - Maroofian, Reza
AU - Silver, David L.
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to European Society of Human Genetics.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Major Facilitator Superfamily Domain containing 2a (MFSD2A) is an essential endothelial lipid transporter at the blood-brain barrier. Biallelic variants affecting function in MFSD2A cause autosomal recessive primary microcephaly 15 (MCPH15, OMIM# 616486). We sought to expand our knowledge of the phenotypic spectrum of MCPH15 and demonstrate the underlying mechanism of inactivation of the MFSD2A transporter. We carried out detailed analysis of the clinical and neuroradiological features of a series of 27 MCPH15 cases, including eight new individuals from seven unrelated families. Genetic investigation was performed through exome sequencing (ES). Structural insights on the human Mfsd2a model and in-vitro biochemical assays were used to investigate the functional impact of the identified variants. All patients had primary microcephaly and severe developmental delay. Brain MRI showed variable degrees of white matter reduction, ventricular enlargement, callosal hypodysgenesis, and pontine and vermian hypoplasia. ES led to the identification of six novel biallelic MFSD2A variants (NG_053084.1, NM_032793.5: c.556+1G>A, c.748G>T; p.(Val250Phe), c.750_753del; p.(Cys251SerfsTer3), c.977G>A; p.(Arg326His), c.1386_1435del; p.(Gln462HisfsTer17), and c.1478C>T; p.(Pro493Leu)) and two recurrent variants (NM_032793.5: c.593C>T; p.(Thr198Met) and c.476C>T; p.(Thr159Met)). All these variants and the previously reported NM_032793.5: c.490C>A; p.(Pro164Thr) resulted in either reduced MFSD2A expression and/or transport activity. Our study further delineates the phenotypic spectrum of MCPH15, refining its clinical and neuroradiological characterization and supporting that MFSD2A deficiency causes early prenatal brain developmental disruption. We also show that poor MFSD2A expression despite normal transporter activity is a relevant pathomechanism in MCPH15.
AB - Major Facilitator Superfamily Domain containing 2a (MFSD2A) is an essential endothelial lipid transporter at the blood-brain barrier. Biallelic variants affecting function in MFSD2A cause autosomal recessive primary microcephaly 15 (MCPH15, OMIM# 616486). We sought to expand our knowledge of the phenotypic spectrum of MCPH15 and demonstrate the underlying mechanism of inactivation of the MFSD2A transporter. We carried out detailed analysis of the clinical and neuroradiological features of a series of 27 MCPH15 cases, including eight new individuals from seven unrelated families. Genetic investigation was performed through exome sequencing (ES). Structural insights on the human Mfsd2a model and in-vitro biochemical assays were used to investigate the functional impact of the identified variants. All patients had primary microcephaly and severe developmental delay. Brain MRI showed variable degrees of white matter reduction, ventricular enlargement, callosal hypodysgenesis, and pontine and vermian hypoplasia. ES led to the identification of six novel biallelic MFSD2A variants (NG_053084.1, NM_032793.5: c.556+1G>A, c.748G>T; p.(Val250Phe), c.750_753del; p.(Cys251SerfsTer3), c.977G>A; p.(Arg326His), c.1386_1435del; p.(Gln462HisfsTer17), and c.1478C>T; p.(Pro493Leu)) and two recurrent variants (NM_032793.5: c.593C>T; p.(Thr198Met) and c.476C>T; p.(Thr159Met)). All these variants and the previously reported NM_032793.5: c.490C>A; p.(Pro164Thr) resulted in either reduced MFSD2A expression and/or transport activity. Our study further delineates the phenotypic spectrum of MCPH15, refining its clinical and neuroradiological characterization and supporting that MFSD2A deficiency causes early prenatal brain developmental disruption. We also show that poor MFSD2A expression despite normal transporter activity is a relevant pathomechanism in MCPH15.
UR - https://www.scopus.com/pages/publications/85086787908
UR - https://www.scopus.com/pages/publications/85086787908#tab=citedBy
U2 - 10.1038/s41431-020-0669-x
DO - 10.1038/s41431-020-0669-x
M3 - Article
C2 - 32572202
AN - SCOPUS:85086787908
SN - 1018-4813
VL - 28
SP - 1509
EP - 1519
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 11
ER -